Calliditas Therapeutics Logo

Calliditas Therapeutics

Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.

CALTX | ST

Overview

Corporate Details

ISIN(s):
SE0010441584 (+1 more)
LEI:
549300PVPZO8TNT76B58
Country:
Sweden
Address:
Box 70351, 107 24 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases (orphan indications) with significant unmet medical needs. The company's pipeline has an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide) in the U.S. and marketed as Kinpeygo® in Europe, is a novel therapeutic developed to treat primary IgA nephropathy (IgAN). Calliditas leverages its scientific and commercial expertise and seeks strategic partnerships to advance the development and global commercialization of its therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-16 15:30
Delisting Announcement
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
English 134.8 KB
2024-09-16 15:30
Delisting Announcement
Avnotering av Calliditas Therapeutics AB (publ) från Nasdaq Stockholm
Swedish 134.6 KB
2024-08-13 07:00
Interim / Quarterly Report
Swedish 2.0 MB
2024-08-13 07:00
Interim / Quarterly Report
English 2.0 MB
2024-08-06 11:00
Major Shareholding Notification
English 34.7 KB
2024-08-05 13:51
Major Shareholding Notification
English 34.5 KB
2024-07-31 14:00
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Calliditas Therapeutics
Swedish 180.0 KB
2024-07-31 14:00
Share Issue/Capital Change
Number of shares and votes in Calliditas Therapeutics
English 120.7 KB
2024-07-26 08:00
Earnings Release
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliar…
English 219.4 KB
2024-07-26 08:00
Regulatory Filings
Calliditas utläser positiva topline-data från fas 2b-studien TRANSFORM i primär…
Swedish 223.3 KB
2024-06-17 17:30
AGM Information
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ)
Swedish 158.0 KB
2024-06-17 17:30
AGM Information
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
English 141.0 KB
2024-06-04 10:15
Major Shareholding Notification
English 34.1 KB
2024-05-30 20:00
Legal Proceedings Report
Calliditas partner STADA får positivt yttrande från CHMP som rekommenderar ett …
Swedish 176.3 KB
2024-05-30 20:00
Legal Proceedings Report
Calliditas partner STADA receives positive CHMP opinion recommending full appro…
English 177.8 KB

Automate Your Workflow. Get a real-time feed of all Calliditas Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Calliditas Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Calliditas Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-23 Diane Parks Other Other 4,086 N/A
2024-07-04 Fredrik Johansson Other Sell 36,000 7,408,800.00 SEK
2024-07-04 Fredrik Johansson Other Sell 31,439 6,476,434.00 SEK
2024-07-04 Fredrik Johansson Other Buy 40,939 N/A
2024-07-03 Frank Bringstrup Other Sell 8,000 1,646,400.00 SEK
2024-07-02 Richard Philipson Other Sell 27,209 5,591,177.41 SEK
2024-07-02 Frank Bringstrup Other Sell 9,796 2,012,980.04 SEK
2024-07-02 Sandra Boström Frithiof Other Sell 6,530 1,341,849.70 SEK
2024-07-01 Richard Philipson Other Sell 23,676 4,866,838.56 SEK
2024-07-01 Frank Bringstrup Other Sell 8,523 1,751,987.88 SEK

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.